These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21789609)

  • 1. Proposing a method of regional assessment and a novel outcome measure in rheumatoid arthritis.
    Nishiyama S; Aita T; Yoshinaga Y; Kishimoto H; Toda M; Yoshihara Y; Miyoshi S; Manki A; Miyawaki S
    Rheumatol Int; 2012 Aug; 32(8):2569-71. PubMed ID: 21789609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
    Kameda H; Sekiguchi N; Nagasawa H; Amano K; Takei H; Suzuki K; Nishi E; Ogawa H; Takeuchi T
    Mod Rheumatol; 2006; 16(6):381-8. PubMed ID: 17165001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.
    Terenzi R; Santoboni G; Bartoloni E; Alunno A; Luccioli F; Gerli R
    Clin Exp Rheumatol; 2015; 33(3):445. PubMed ID: 25937244
    [No Abstract]   [Full Text] [Related]  

  • 6. Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.
    Suzuki T; Hirota T; Ogishima H; Umeda N; Kondo Y; Yokosawa M; Miki H; Tsuboi H; Matsumoto I; Sumida T
    Int J Rheum Dis; 2015 Jan; 18(1):108-10. PubMed ID: 25294091
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
    Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM;
    Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series.
    Epis O; Filippucci E; Delle Sedie A; De Matthaeis A; Bruschi E
    Rheumatol Int; 2014 May; 34(5):737-42. PubMed ID: 23354163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre observational study comparing patient reported outcomes to assess reliability of swollen and tender joint assessments and response to certolizumab treatment as compared to clinician assessments in rheumatoid arthritis.
    Inderjeeth CA; Inderjeeth AJ; Raymond WD
    Int J Rheum Dis; 2019 Jan; 22(1):73-80. PubMed ID: 30187688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
    Yamanaka H; Tanaka Y; Inoue E; Hoshi D; Momohara S; Hanami K; Yunoue N; Saito K; Amano K; Kameda H; Takeuchi T
    Mod Rheumatol; 2011 Apr; 21(2):122-33. PubMed ID: 20953815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2).
    Tanaka Y; Takeuchi T; Inoue E; Saito K; Sekiguchi N; Sato E; Nawata M; Kameda H; Iwata S; Amano K; Yamanaka H
    Mod Rheumatol; 2008; 18(2):146-52. PubMed ID: 18283523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-enhanced whole body joint MR imaging in rheumatoid patients on tumour necrosis factor-alpha agents: a pilot study to evaluate novel scoring system for MR synovitis.
    Kamishima T; Kato M; Atsumi T; Koike T; Onodera Y; Terae S
    Clin Exp Rheumatol; 2013; 31(1):154. PubMed ID: 23190694
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials.
    Pincus T; Amara I; Segurado OG; Bergman M; Koch GG
    J Rheumatol; 2008 Feb; 35(2):201-5. PubMed ID: 18050378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: Potential utility of power doppler sonography in clinical practice.
    Fukae J; Isobe M; Kitano A; Henmi M; Sakamoto F; Narita A; Ito T; Mitsuzaki A; Shimizu M; Tanimura K; Matsuhashi M; Kamishima T; Atsumi T; Koike T
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1247-53. PubMed ID: 21671420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
    Klarenbeek NB; Güler-Yüksel M; van der Heijde DM; Hulsmans HM; Kerstens PJ; Molenaar TH; de Sonnaville PB; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2010 Dec; 69(12):2107-13. PubMed ID: 20610442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial.
    Stohl W; Gomez-Reino J; Olech E; Dudler J; Fleischmann RM; Zerbini CA; Ashrafzadeh A; Grzeschik S; Bieraugel R; Green J; Francom S; Dummer W
    Ann Rheum Dis; 2012 Aug; 71(8):1289-96. PubMed ID: 22307942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.